Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-01-03 Sale |
2025-01-07 5:16 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
8,966 | $12.18 | $109,206 | 77,388 (Direct) |
View |
| 2024-01-08 Sale |
2024-01-10 4:15 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
2,275 | $28.87 | $65,682 | 43,927 (Direct) |
View |
| 2024-01-03 Sale |
2024-01-05 4:50 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
5,532 | $29.46 | $162,973 | 46,202 (Direct) |
View |
| 2023-01-04 Sale |
2023-01-06 5:39 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
4,838 | $37.82 | $182,982 | 17,629 (Direct) |
View |
| 2022-01-01 Sale |
2022-03-03 8:03 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
1,148 | $112.25 | $128,863 | 42,947 (Direct) |
View |
| 2021-08-30 Sale |
2021-09-01 7:34 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
97,000 | $154.83 | $15,018,054 | 164,391 (Direct) |
View |
| 2021-08-04 Sale |
2021-08-06 6:19 pm |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
26,000 | $138.24 | $3,594,357 | 111,391 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-01-01 Exercise |
2025-01-03 4:30 pm |
2025-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
3,500 | $0 | 86,354 (Direct) |
View |
| 2024-05-29 Option Award |
2024-05-31 4:15 pm |
N/A 2034-05-29 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
147,660 | $0 | 147,660 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-05 4:10 pm |
N/A 2034-02-28 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
92,760 | $0 | 136,687 (Direct) |
View |
| 2024-01-01 Exercise |
2024-01-03 5:35 pm |
2024-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
3,500 | $0 | 55,234 (Direct) |
View |
| 2023-06-22 Option Award |
2023-06-26 4:50 pm |
N/A 2033-06-22 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
36,200 | $0 | 36,200 (Direct) |
View |
| 2023-03-01 Option Award |
2023-03-03 5:14 pm |
N/A 2033-02-28 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
72,240 | $0 | 89,869 (Direct) |
View |
| 2023-01-01 Exercise |
2023-01-04 8:38 pm |
2023-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
3,500 | $0 | 29,467 (Direct) |
View |
| 2022-06-17 Option Award |
2022-06-22 4:41 pm |
N/A 2032-06-17 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2022-03-01 Option Award(A) |
2022-03-04 8:58 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
20,203 | $0 | 20,203 (Direct) |
View |
| 2022-01-01 Exercise |
2022-03-03 8:03 pm |
2022-01-01 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
3,500 | $0 | 42,947 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-03 8:03 pm |
N/A 2032-02-28 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
13,816 | $0 | 42,947 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:34 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
27,000 | $13.4 | 164,391 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:34 pm |
N/A 2030-03-01 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
97,000 | $0 | 164,391 (Direct) |
View |
| 2021-08-30 Exercise |
2021-09-01 7:34 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
70,000 | $14.25 | 164,391 (Direct) |
View |
| 2021-08-04 Exercise |
2021-08-06 6:19 pm |
N/A N/A |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
26,000 | $13.4 | 111,391 (Direct) |
View |
| 2021-08-04 Exercise |
2021-08-06 6:19 pm |
N/A 2030-03-01 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
26,000 | $0 | 111,391 (Direct) |
View |
| 2021-06-17 Option Award |
2021-06-21 5:01 pm |
N/A 2031-06-17 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
15,500 | $0 | 15,500 (Direct) |
View |
| 2021-03-03 Option Award |
2021-03-05 5:54 pm |
N/A 2031-03-02 |
Intellia Therapeutics Inc. | NTLA | Sepp-Lorenzino Laura EVP, Chief Scientific Officer |
98,000 | $0 | 98,000 (Direct) |
View |
| 2020-11-23 Option Award |
2020-11-24 4:42 pm |
N/A 2030-11-23 |
Taysha Gene Therapies Inc. | TSHA | Sepp-Lorenzino Laura Director |
31,000 | $0 | 31,000 (Direct) |
View |